Evidence map›Paper›PMID 42344235›Full record

ArticleInfection and drug resistance2026

Efficacy of Vonoprazan-Doxycycline Dual Therapy for the Treatment of

Xue Zhang, Qingrui Li, Yanhong Deng, Xilong Zhang, Ruijuan Xin, Tingting Yang, Xiaole Guo, Xiaoqin Ma, Xue Li, Yuanyuan Tang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xue Zhang *Department of Gastroenterology, The Third Clinical College, Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China.ORCID 0009-0002-0251-5270
Qingrui Li *Department of Gastroenterology, The Third Clinical College, Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China.
Yanhong Deng *Department of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, People's Republic of China.
Xilong Zhang *Department of Gastroenterology, The Third People's Hospital of Shizuishan City, Shizuishan, Ningxia, People's Republic of China.
Ruijuan XinDepartment of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, People's Republic of China.
Tingting YangDepartment of Gastroenterology, The Third Clinical College, Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China.
Xiaole GuoDepartment of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, People's Republic of China.
Xiaoqin MaDepartment of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, People's Republic of China.
Xue LiDepartment of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, People's Republic of China.
Yuanyuan TangDepartment of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, People's Republic of China.
Ruifang GuoDepartment of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, People's Republic of China.
Linke MaDepartment of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, People's Republic of China.
Zhanbin HouDepartment of Gastroenterology, Yanchi County People's Hospital, Wuzhong, Ningxia, People's Republic of China.
Jinjuan WangDepartment of Gastroenterology, Yanchi County People's Hospital, Wuzhong, Ningxia, People's Republic of China.
Na HouDepartment of Gastroenterology, Yanchi County People's Hospital, Wuzhong, Ningxia, People's Republic of China.
Shengjuan HuDepartment of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To compare the efficacy and safety of vonoprazan-doxycycline dual therapy versus vonoprazan-amoxicillin high-dose dual therapy as first-line eradication treatment for Methods: This retrospective study collected clinical data from 357 patients with confirmed Results: ITT eradication rates were 76.1% (137/180) in the doxycycline group and 78.0% (138/177) in the amoxicillin group, with both falling below the commonly accepted 80% threshold for first-line therapy; PP eradication rates were 87.3% (137/157) and 89.0% (138/155), respectively. No statistically significant differences were observed in either analysis (both Conclusion: Vonoprazan-doxycycline dual therapy may achieve comparable eradication efficacy to vonoprazan-amoxicillin dual therapy for

Indexed as

adverse eventsamoxicillindoxycyclineeradication rateHelicobacter pyloriretrospective studyvonoprazan

Identifiers

PMID42344235
PMCPMC13289632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.